The Portfolio returned 7.33% gross, significantly outperforming the MSCI World Health Care Index's 3.12% return. Click here ...

For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...

Through the first three quarters of 2025, M&A activity overtook the entire 2024 total, according to Endpoints News. Editor and founder John Carroll wrote in October this might be the best time in 15 ...

Wave's bullish start to the week was driven by the encouraging readout of a Phase 1 clinical study of WVE-007, its obesity drug candidate. Weight-loss drugs are all the rage these days in the U.S., ...

The average one-year price target for Wave Life Sciences (NasdaqGM:WVE) has been revised to $32.70 / share. This is an increase of 60.82% from the prior estimate of $20.34 dated December 3, 2025. The ...

The developer behind Philadelphia's largest life sciences building says the market needs patience after venture capital ...

Salesforce (NYSE: CRM), the world’s #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global innovative ...

The Board on Life Sciences (BLS) was established in 1984 to serve as the focal point for addressing critical, emerging policy and technical issues associated with the life sciences and biotechnology ...

Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and more. Click for this WVE stock update.

Life Sciences ventures face high levels of scientific, clinical and commercial pathway uncertainty, and these uncertainties present many opportunities for entrepreneurial innovation. This course is ...

The 2024-25 Sustainability Report reflects the company’s long-term view-one that places science, responsibility, and ...

Then, life science companies were scrambling for space — industrial vacancy rates dipped to as low as 2%. Deep‑pocketed developers from Silicon Valley and Boston came and spent millions speculating on ...